Immunogenic properties of a chimeric plant virus expressing a Hepatitis C virus (HCV)-derived epitope: New prospects for an HCV vaccine

Journal of Clinical Immunology

Volumn 25, Issue 2, 2005, Pages 142-152

  Piazzolla, G ^a   Nuzzaci, M ^b   Tortorella, C ^a   Panella, E ^a   Natilla, A ^b   Boscia, D ^c   De Stradis, A ^c   Piazzolla, P ^b   Antonaci, S ^a  

^a UNIVERSITY OF BARI   (Italy)

^b UNIVERSITY OF BASILICATA   (Italy)

^c CNR   (Italy)

Author keywords

CMV; Cytokines; HCV vaccine; Plant viruses; T lymphocytes

Indexed keywords

CD3 ANTIGEN; CD8 ANTIGEN; EPITOPE; GAMMA INTERFERON; GLYCOPROTEIN E1; HEPATITIS C VACCINE; INTERLEUKIN 12; INTERLEUKIN 15;

ADULT; AGED; AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOENGINEERING; CLINICAL ARTICLE; CONTROLLED STUDY; CUCUMBER MOSAIC VIRUS; CYTOKINE PRODUCTION; CYTOKINE RELEASE; FEMALE; HEPATITIS C VIRUS; HUMAN; HUMORAL IMMUNITY; IMMUNOGENETICS; LYMPHOCYTE CULTURE; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PLANT VIRUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RABBIT; T LYMPHOCYTE;

ADULT; AGED; ANIMALS; CELLS, CULTURED; CHIMERA; CHRONIC DISEASE; CUCUMOVIRUS; CYTOKINES; EPITOPES; FEMALE; HEPACIVIRUS; HEPATITIS C; HUMANS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; RABBITS; T-LYMPHOCYTES; VIRAL HEPATITIS VACCINES;

EID: 17744393221     PISSN: 02719142     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10875-005-2820-4     Document Type: Article

References (59)

1. Wasley A, Alter MJ: Epidemiology of hepatitis C: Geographic, differences and temporal trends. Semin Liver Dis 20:1-16, 2000
2. Lechmann M, Ihlenfeldt HG, Braunschweiger I, Giers G, Jung G, Matz B, et al.: T- and B-cell responses to different hepatitis C virus antigens in patients with chronic hepatitis C infection and in healthy anti-hepatitis C virus-positive blood donors without viremia. Hepatology 24:790-795, 1996
3. Rehermann B, Chisari FV: Cell mediated immune response to the hepatitis C virus. Curr Top Microbiol Immunol 242:299-325, 2000
4. Freeman AJ, Marines G, French RA, Lloyd AR: Immunopathogenesis of hepatitis C virus infection. Immunol Cell Biol 79:515-536, 2001
5. Memon ML, Memon MA: Hepatitis C: An epidemiological review. J Viral Hepatol 9:84-100, 2002
6. Rosenberg S: Recent advances in the molecular biology of hepatitis C virus. J Mol Biol 313:451-464, 2001
7. Manns MP, McHutchinson JC, Gordon SC, Rustgi VK, Shiffman ML, Reindollar R, et al.: Peginterferon α-2b plus ribavirin compared with interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 358:958-965, 2001
8. Lechner F, Wong D, Dunbar P, Chapman R, Chung R, Dohrenwend P, Robbins G, et al.: Analysis of a successful immune response in persons infected with hepatitis C virus. J Exp Med 191:1499-1512, 2000
9. Ferrari C, Valli A, Galati L, Penna A, Scaccaglia P, Giuberti T, et al.: T-cell response to structural and nonstructural Hepatitis C virus antigens in persistent and self-limited Hepatitis C virus infections. Hepatology 19:286-295, 1994
10. Missale G, Bertoni R, Lamonaca V, Valli A, Massari M, Mori C, et al.: Different clinical behaviours of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. J Clin Invest 98:706-714, 1996
11. + T lymphocyte responses are induced during acute hepatitis C virus infection but are not sustained. Eur J Immunol 30:2479-2487, 2000
12. Takaki A, Wiese M, Maertens G, Depla E, Seifert U, Liebetrau A, et al.: Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med 6:578-582, 2000
13. Houghton M: Strategies and prospects for vaccination against the hepatitis C virus. Curr Top Microbiol Immunol 242:327-329, 2000
14. Lechmann M, Liang TJ: Vaccine development for hepatitis C. Semin Liver Dis 20:211-226, 2000
15. Robertson B, Myers G, Howard C, Brettin T, Bukh J, Gaschen B, et al.: Classification, nomenclature and database development for hepatitis C virus (HCV) and related viruses: Proposals for standardization. International Committee on Virus Taxonomy. Arch Virol 143:2493-2503, 1998
16. Shimizu YK, Igarashi H, Kiyohara T, Cabezon T, Farci P, Purcell RH, et al.: A hyperimmune serum against a synthetic peptide corresponding to the hypervariable region 1 of hepatitis C virus can prevent viral infection in cell cultures. Virology 223:409-412, 1996
17. Farci P, Shimoda A, Wong D, Cabezon T, De Gioannis D, Strazzera A, et al.: Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc Natl Acad Sci USA 93:15394-15399, 1996
18. Savelyeva N, Munday R, Spellerberg MB, Lomonossoff GP, Stevenson FK: Plant viral genes in DNA idiotypic vaccines activate linked CD4+ T-cell mediated immunity against B-cell malignancies. Nat Biotechnol 19:760-764, 2001
19. McLain L, Porta C, Lomonossoff GP, Durrani Z, Dimmock NJ: Human immunodeficiency virus type 1 neutralizing antibodies raised to a gp41 peptide expressed on the surface of a plant virus. AIDS Res Hum Retroviruses 11:327-334, 1995
20. McLain L, Durrani Z, Wisniewski LA, Porta C, Lomonossoff GP, Dimmock NJ: Stimulation of neutralizing antibodies to human immunodeficiency virus type 1 in three strains of mice immunized with a 22-mer amino acid peptide expressed on the surface of a plan virus. Vaccine 14:799-810, 1996
21. Marusic C, Rizza P, Lattanzi L, Mancini C, Spada M, Belardelli F, et al.: Chimeric plant virus particles as immunogens for inducing murine and human immune responses against human immunodeficiency virus type 1. J Virol 75:8434-8439, 2001
22. Natilla A, Piazzolla G, Nuzzaci M, Saldarelli P, Tortorella C, Antonaci S, et al.: Cucumber mosaic virus as a carrier of a hepatitis C virus-derived epitope. Arch Virol 149:137-154, 2004
23. Puntoriero G, Meola A, Lahm A, Zucchelli S, Bruni EB, Tafi R, et al.: Towards a solution for hepatitis C hypervariability: Mimotopes of the hypervariable region 1 can induce antibodies cross-reacting with a large number of viral variants. EMBO J 17:3521-3533, 1998
24. Lot H, Marrou J, Quiot JB, Esvan C: Contribution à l'étude du virus de la mosaique du concombre (CMV). I: Methode de purification rapide du virus. Ann Phytopathol 14:25-38, 1972
25. Scheuer PJ: Classification of chronic viral hepatitis: A need for reassessment. J Hepatol 13:372-374, 1991
26. Usha R, Rohll JB, Spall VE, Shanks M, Maule AJ, Johnson JE, et al.: Expression of an animal virus antigenie site on the surface of a plant virus particle. Virology 197:366-374, 1993
27. Porta C, Spall VE, Loveland J, Johnson JE, Barker PJ, Lomonosoff GP: Development of cowpea mosaic virus as a high-yielding system for the presentation of foreign peptides. Virology 202:949-955, 1994
28. Turpen TH, Reinl SJ, Charoenvit Y, Hoffman SL, Fallarme V, Grill L: Malarial epitopes expressed on the surface of reeombinant tobacco mosaic vrus. Biotechnology 13:53-57, 1995
29. Fitchen J, Beachy RN, Hein MB: Plant virus expressing hybrid coat protein with added murine epitope elicits autoantibodies response. Vaccine 13:1051-1057, 1995
30. Nemchinov LG, Liang TJ, Rifaat MM, Mazyad HM, Hadidi A, Keith JM: Development of a plant-derived subunit vaccine candidate against hepatitis C virus. Arch Virol 145:2557-2573, 2000
31. Arazi T, Huang PL, Huang P, Zhang L, Shiboleth YM, Gal-On A, Lee-Huang S: Production of antiviral and antitumor proteins MAP30 and GAP31 in cucurbits using the plant virus vector ZYMV-AGII. Biochem Biophys Res Commun 292:441-448, 2002
32. Nicholas BL, Brennan FR, Martinez-Torrecuadrada JL, Casal JI, Hamilton WD, Wakelin D: Characterization of the immune response to canine parvovirus induced by vaccination with chimaeric plant viruses. Vaccine 20:2727-2734, 2002
33. Yusibov V, Hooper DC, Spitsin SV, Fleysh N, Kean RB, Mikheeva T, et al.: Expression in plants and inimunogenicity of plant virus-based experimental rabies vaccine. Vaccine 20:3155-3164, 2002
34. Yusibov V, Koprowski H: Plants as vector for biomedical products. J Med Food 1:5-12, 1998
35. Giddings G, Allison G, Brooks D, Carter A: Transgenic plants as factories for biopharmaceuticals. Nat Biotechnol 18:1151-1155, 2000
36. Ashwell JD, Weissman AM: T-cell antigen receptor genes, gene products and coreceptors. In Clinical Immunology, 5th edn, Vol. 1, RR Rich, TA Fleisher, WT Shearer, BL Kotzin, HW Schroeder (eds). London, Mosby, 2001, pp 5.1-5.19
37. Valitutti S, Dessing M, Aktories K, Gallati H, Lanzavecchia A: Sustained signaling leading to T cell activation results from prolonged T cell receptor occupancy. Role of T cell actin cytoskeleton. J Exp Med 181:577-584, 1995
38. Valitutti S, Muller S, Dessing M, Lanzavecchia A: Different responses are elicited in cytotoxic T lymphocytes by different levels of T cell receptor occupancy. J Exp Med 183:1917-1921, 1996
39. Viola A, Lanzavecchia A: T cell activation determined by T cell receptor number and tunable thresholds. Science (Wash DC) 273:104-106, 1996
40. + T cells. J Exp Med 185:641-651, 1997
41. Trimble LA, Kam LW, Friedman RS, Xu Z, Lieberman J: CD3ζ and CD28 down-modulation on CD8 T cells during viral infection. Blood 96:1021-1029, 2000
42. Jason J, Inge KL: Modulation of CD8 and CD3 by HIV or HIV antigens. Scand J Immunol 53:259-267, 2001
43. Wack A, Soldaini E, Tseng CK, Nuti S, Klimpel GR, Abrignani S: Binding of the hepatitis C virus envelope protein E2 to CD81 provides a co-stimulatory signal for human T cells. Eur J Immunol 31:166-175, 2001
44. Cormier EG, Tsamis F, Kajumo F, Durso RJ, Gardner JP, Dragic T: CD81 is an entry coreceptor for hepatitis C virus. Proc Natl Acad Sci USA 101:7270-7274, 2004
45. Pileri P Uematsu Y Campagnoli S Galli G Falugi F Petracca R, et al.: Binding of hepatitis C virus to CD81. Science 282:938-941, 1998
46. Piazzolla G, Tortorella C, Schiraldi S, Antonaci S: Relationship between interferon-γ, interleukin-10, and interleukin-12 production in chronic hepatitis C and in vitro effects of interferon-α. J Clin Immunol 20:54-61, 2000
47. Piazzolla G, Tortorella C, Fiore G, Fanelli M, Pisconti A, Antonaci S: Interleukin-12 p40/p70 ratio and in vivo responsiveness to IFN-α treatment in chronic hepatitis C. J Interferon Cytokine Res 21:453-461, 2001
48. + progenitor-derived dendritic cell vaccine. Cancer Res 61:6451-6458, 2001
49. Belli F, Testori A, Rivoltini L, Maio M, Andreola G, Sertoli MR, et al.: Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: Clinical and immunologic findings. J Clin Oncol 20:4169-4180, 2002
50. Scheibenbogen C, Nagorsen D, Seliger B, Schmittel A, Letsch A, Bauer S, et al.: Long-term freedom from recurrence in 2 stage IV melanoma patients following vaccination with tyrosinase peptides. Int J Cancer 99:403-408, 2002
51. Rehermann B, Chang K-M, McHutchinson JC, Kokka R, Houghton M, Chisari FV: Quantitative analysis of the peripheral blood cytotoxic T lymphocyte response in patients with chronic hepatitis C virus infection. J Clin Invest 98:1432-1440, 1996
52. Waldrop SL, Pitcher CJ, Peterson DM, Maino VC, Picker LJ: Determination of antigen-specific memory-effector CD4+ T cell frequencies by flow cytometry. J Clin Invest 99:1739-1750, 1997
53. Suni MA, Picker LJ, Maino C: Detection of antigen-specific T cell cytokine expression in whole blood by flow cytometry. J Immunol Methods 212:89-98, 1998
54. Somani J, Lonial S, Rosenthal H, Resnick S, Kakhniashvili I, Waller EK: A randomized, placebo-controlled trial of subcutaneous administration of GM-CSF as a vaccine adjuvant: Effect on cellular and humoral immune responses. Vaccine 21:221-230, 2002
55. Frasca L, Scottà C, Del Porto P, Nicosia A, Pasquazzi C, Versace I, et al.: Antibody-selected mimics of hepatitis C virus hypervariable region 1 activate both primary and memory Th lymphocytes. Hepatology 38:653-663, 2003
56. Harris N, Duller RM, Kampiah G: Gamma interferon-induced, nitric oxide-mediated inhibition of vaccinia virus replication. J Virol 69:910-915, 1995
57. Matsui M, Moriya O, Abdel-Aziz N, Matsuura Y, Miyamura T, Akatsuka T: Induction of hepatitis C virus-specific cytotoxic T lymphocytes in mice by immunization with dendritic cells transduced with replication-defective recombinant adenovirus. Vaccine 21:211-220, 2002
58. Thimme RD, Oldach D, Chang KM, Steiger C, Ray SC, Chisari SV: Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 19:1395-1406, 2001
59. + T lymphocytes after infection with hepatitis C virus. J Virol 75:2088-2097, 2001